SCIENCE 37 HOLDINGS INC (SNCE) Stock Price, Forecast & Analysis

NASDAQ:SNCE • US8086442071

5.75 USD
+0.02 (+0.35%)
At close: Mar 11, 2024
5.7203 USD
-0.03 (-0.52%)
After Hours: 3/11/2024, 6:05:35 PM

SNCE Key Statistics, Chart & Performance

Key Statistics
Market Cap34.67M
Revenue(TTM)60.27M
Net Income(TTM)-124.65M
Shares6.03M
Float5.01M
52 Week High12.96
52 Week Low3.73
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-7.26
PEN/A
Fwd PEN/A
Earnings (Next)05-13
IPO2020-11-20
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
SNCE short term performance overview.The bars show the price performance of SNCE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 -10

SNCE long term performance overview.The bars show the price performance of SNCE in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of SNCE is 5.75 USD. In the past month the price increased by 1.23%. In the past year, price decreased by -19.47%.

SCIENCE 37 HOLDINGS INC / SNCE Daily stock chart

SNCE Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to SNCE. When comparing the yearly performance of all stocks, SNCE is a bad performer in the overall market: 70.82% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
SNCE Full Technical Analysis Report

SNCE Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to SNCE. While SNCE seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
SNCE Full Fundamental Analysis Report

SNCE Financial Highlights

Over the last trailing twelve months SNCE reported a non-GAAP Earnings per Share(EPS) of -7.26. The EPS decreased by -881.08% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -164.66%
ROE -241.1%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-429.41%
Sales Q2Q%-8.37%
EPS 1Y (TTM)-881.08%
Revenue 1Y (TTM)-19.21%
SNCE financials

SNCE Forecast & Estimates

10 analysts have analysed SNCE and the average price target is 14.11 USD. This implies a price increase of 145.39% is expected in the next year compared to the current price of 5.75.

For the next year, analysts expect an EPS growth of -72.66% and a revenue growth -14.69% for SNCE


Analysts
Analysts76
Price Target14.11 (145.39%)
EPS Next Y-72.66%
Revenue Next Year-14.69%
SNCE Analyst EstimatesSNCE Analyst Ratings

SNCE Ownership

Ownership
Inst Owners0.02%
Ins Owners287.18%
Short Float %N/A
Short RatioN/A
SNCE Ownership

SNCE Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
TMO THERMO FISHER SCIENTIFIC INC20.81191.962B
DHR DANAHER CORP24.83148.096B
BRKRP BRUKER CORP - BRKR 6 3/8 09/01/28141.9846.374B
A AGILENT TECHNOLOGIES INC20.5234.761B
IQV IQVIA HOLDINGS INC12.4128.089B
MTD METTLER-TOLEDO INTERNATIONAL30.1428.006B
WAT WATERS CORP22.6619.843B
ILMN ILLUMINA INC23.2817.98B
WST WEST PHARMACEUTICAL SERVICES31.1117.346B
MEDP MEDPACE HOLDINGS INC26.4712.783B

About SNCE

Company Profile

SNCE logo image Science 37 Holdings Inc is a US-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Research Triangle Park, North Carolina and currently employs 460 full-time employees. The company went IPO on 2020-11-20. Science 37 Holdings, Inc. is engaged in patient-centric clinical trials and in supporting novel approaches to decentralized clinical trial designs. Through its patient-centric approach, it reduces the impact of the geographic barriers associated with conventional physical clinical trial sites, enabling recruitment of virtually any patient. Its offerings lie in its configurable unified technology platform combined with its centralized patient recruitment capabilities and specialized network of patient communities. Its unified technology platform is purpose-built for patient-centric clinical trial execution and is designed to provide an end-to-end, single stop solution. The company also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, and remote coordinators designed for the purpose of orchestrating patient-centric clinical trials. The company uses diversified, multi-channel programs to identify patients who fit the profile for each of its projects.

Company Info

SCIENCE 37 HOLDINGS INC

800 Park Offices Drive, Suite 3606

RESEARCH TRIANGLE PARK NORTH CAROLINA US

CEO: Andrew McDonald

Employees: 460

SNCE Company Website

Phone: 19843773737

SCIENCE 37 HOLDINGS INC / SNCE FAQ

What does SNCE do?

Science 37 Holdings Inc is a US-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Research Triangle Park, North Carolina and currently employs 460 full-time employees. The company went IPO on 2020-11-20. Science 37 Holdings, Inc. is engaged in patient-centric clinical trials and in supporting novel approaches to decentralized clinical trial designs. Through its patient-centric approach, it reduces the impact of the geographic barriers associated with conventional physical clinical trial sites, enabling recruitment of virtually any patient. Its offerings lie in its configurable unified technology platform combined with its centralized patient recruitment capabilities and specialized network of patient communities. Its unified technology platform is purpose-built for patient-centric clinical trial execution and is designed to provide an end-to-end, single stop solution. The company also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, and remote coordinators designed for the purpose of orchestrating patient-centric clinical trials. The company uses diversified, multi-channel programs to identify patients who fit the profile for each of its projects.


Can you provide the latest stock price for SCIENCE 37 HOLDINGS INC?

The current stock price of SNCE is 5.75 USD. The price increased by 0.35% in the last trading session.


What is the dividend status of SCIENCE 37 HOLDINGS INC?

SNCE does not pay a dividend.


What is the ChartMill technical and fundamental rating of SNCE stock?

SNCE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the analyst forecast for SNCE stock?

10 analysts have analysed SNCE and the average price target is 14.11 USD. This implies a price increase of 145.39% is expected in the next year compared to the current price of 5.75.


What is the market capitalization of SNCE stock?

SCIENCE 37 HOLDINGS INC (SNCE) has a market capitalization of 34.67M USD. This makes SNCE a Nano Cap stock.